跳到正文
BioPharm International·· 11 天前AI 评分32

问答:AI在药物开发中出错时谁来担责?——赛诺菲、Open Biopharma与GxP Frame专家谈AI对药物成功率、人工监督与数据治理的影响

Q&A: Who Is Accountable When AI Gets Drug Development Wrong?

AI 导读

BioPharm International与赛诺菲的Matt Truppo、Open Biopharma的Richard Jaenisch及GxP Frame的Brian Drapeau讨论AI在药物开发与生产中的问责问题。专家审视AI是否能可测量地提高治疗成功率,以及企业如何在AI工作中保持人工判断与数据治理的核心地位。讨论还涉及未来5至10年进入该领域专业人士应有何预期。

正文 · 原文

Commentary|Events|November 11, 2026

Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.

As AI becomes routine in drug development and manufacturing, attention is shifting from what the technology can do to what it can be trusted to do. In this second half of a discussion between BioPharm International® and Sanofi’s Matt Truppo, Open Biopharma’s Richard Jaenisch, and GxP Frame’s Brian Drapeau, the experts examine whether AI measurably improves the odds of therapeutic success, how companies keep human judgment and data governance at the center of AI-enabled work, and what success will look like in the near term. They also note what professionals entering the field should expect over the next 5 to 10 years.

Related to this article

FAQ: Sterility Assurance for Injectable Biologics

November 10th, 2026

This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.

Read more

Doctor holding a digital tablet with x-ray of the 3D head of the patient with pain on the neck. Migraine headache concept | Image credit: © steph photographies - © steph photographies - stock.adobe.com

November 6th, 2026

Johnson & Johnson's amivantamab (Rybrevant Faspro) won accelerated FDA approval for pretreated recurrent head and neck cancer.

Read more

3D rendered medical illustration of male anatomy showing the liver. | Image Credit: © Sebastian Kaulitzki - © Sebastian Kaulitzki - stock.adobe.com

November 5th, 2026

Akeso won NMPA priority review for ivonescimab plus chemotherapy in first-line biliary tract cancer after a phase 3 win over durvalumab plus chemo.

Read more

Sad blue-grey eyes of elderly woman looking to the side, extreme close-up shot | Image credit: © pressmaster - © pressmaster - stock.adobe.com

November 5th, 2026

VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.

Read more

Weight loss pills available: Two dosing pens for subcutaneous injection of antidiabetic medication or anti-obesity medication on a blue background besides a heap of GLP-1 pills. | Image Credit: © Andreas Prott - © Andreas Prott - stock.adobe.com

November 9th, 2026

argenx's acquisition of Unnatural Products adds macrocyclic peptides that could yield oral or long-acting treatments for immune-mediated diseases.

Read more

Elderly man suffering from psoriasis on hands | Image credit: © and.one - © and.one - stock.adobe.com

November 9th, 2026

Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.

Read more

Abstract blue human heart with red cardio pulse line and red circle. Healthcare medical concept | Image credit: © Елена Бутусова - © Елена Бутусова - stock.adobe.com

November 6th, 2026

A real-world study found evolocumab cut fatal or nonfatal heart attack risk 20% vs ezetimibe in adults with ASCVD and prior statin use.

Read more

3D illustration of purple, irregularly shaped cells with spiky projections clustered among red disc-shaped cells on a black background. | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

November 6th, 2026

Oxford spinout Alethio Therapeutics closed a $90 million Series A to take ATX-011, a monoclonal antibody against the G6B receptor, into Phase 1/2a studies in essential thrombocythemia. It is also developing a G6B-targeted ADC for myelofibrosis.

Read more

来源:BioPharm International · biopharminternational.com